Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

Stage IV Chronic Lymphocytic Leukemia Clinical Trial

Official title:

A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00360776
• Other study ID #: NCI-2009-00086
• Secondary ID: 5402CDR000048929
• Status: Terminated
• Phase: Phase 2
• First received: August 3, 2006
• Last updated: April 4, 2017
• Start date: June 2, 2006

Study information

• Verified date: April 2017
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well tipifarnib works in treating patients with anemia or neutropenia and large granular lymphocyte leukemia. Tipifarnib may stop the growth of leukemia by blocking blood flow to the cancer cells and by blocking some of the enzymes needed for cancer cell growth.

Description:

PRIMARY OBJECTIVES:

I. Estimate the complete response rate, partial response rate, and overall response rate in patients with natural killer (NK)- or T-cell-large granular lymphocyte (LGL) leukemia who present with neutropenia or anemia treated with tipifarnib.

SECONDARY OBJECTIVES:

I. Determine the toxicity of tipifarnib in these patients. II. Determine the mechanism of treatment responses in these patients through correlative laboratory studies.

OUTLINE: Patients are stratified by disease type (natural killer-large granular lymphocyte [LGL] leukemia vs T-cell-LGL leukemia).

Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients are evaluated after completion of course 4. Patients achieving complete response receive 1 additional course of treatment. Patients achieving partial response receive 4 additional courses of treatment in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection periodically during study for response mechanism studies and other biomarker correlative studies, including mutations of K-ras and N-ras genes.

After completion of study treatment, patients are followed every 6 months for 5 years.

Other known NCT identifiers

• NCT00331591

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. primary completion date: May 14, 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of T-cell-large granular lymphocyte (LGL) leukemia or natural killer (NK)-LGL leukemia associated with = 1 of the following clinical manifestations:

• Severe neutropenia (i.e., < 500/mm³)

• Neutropenia associated with recurrent infections, meeting 1 of the following criteria: one severe infection requiring hospitalization or at least 2 infections requiring antibiotic therapy

• Symptomatic anemia with significant fatigue with a score of greater than 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale; dyspnea on exertion, but able to walk one flight of stairs without stopping (less than grade 1 respiratory symptoms); cardiac symptoms including worsening of angina or new onset of chest pain

• Transfusion-dependent anemia

• Willing to discontinue use of MTX, Cy, or cyclosporine for 1 month prior to study entry

• T-cell-LGL leukemia must meet all of the following criteria: CD3+ and CD57+ cells > 300/mm³ or CD8+ cells > 650/mm³ by phenotypic studies of peripheral blood, evidence for clonal T-cell receptor gene rearrangement based on positive flow cytometric analysis, T-cell receptor (TCR)-? chain polymerase chain reaction (PCR), TCR-Vß PCR, or by Southern blot analysis

• NK-LGL leukemia must have CD56+ or CD16+ NK cells > 750/mm³ by phenotypic studies of peripheral blood

• Life expectancy > 2 years

• ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

• Fertile patients must use effective contraception prior to and during study

• Negative pregnancy test

• Normal kidney and liver function, as determined by the following laboratory results:

total bilirubin less than or equal to 2.0 mg/dl; AST (SGOT) and ALT (SGPT) less than or equal to 2.5 times the upper limit of normal; and creatinine less than or equal to 2.0 mg/dl

Exclusion Criteria:

• Not pregnant or nursing

• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib

• No allergies to imidazoles (e.g., clotrimazole, ketoconazole, miconazole, econazole, fenticonazole, isoconazole, sulconazole, tioconazole, or terconazole)

• No uncontrolled concurrent illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness or social situations that would limit study compliance

• No other serious medical illness that would limit survival to < 2 years

• No other malignancy within the past 5 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix

• Psychiatric illness that may interfere with study participation

• No other anticancer agents or therapies

• No concurrent antiretroviral therapy for HIV-positive patients

• No other concurrent investigational agents

• No prior tipifarnib or other inhibitors of MAPK signaling intermediates

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid
• Stage III Chronic Lymphocytic Leukemia
• Stage IV Chronic Lymphocytic Leukemia
• T-cell Large Granular Lymphocyte Leukemia

Intervention

Drug:
• tipifarnib
Given orally

Other:
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
United States	Case Western Reserve University	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response rates to tipifarib defined as the proportion of patients achieving a complete response (CCR) or partial response (PR)		Up to 5 years
Secondary	Changes in Ras/ERK and NK receptor expression		Baseline to 5 years